Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
28.81
+1.13 (4.08%)
At close: Jul 21, 2026, 4:00 PM EDT
28.81
0.00 (0.00%)
After-hours: Jul 21, 2026, 5:44 PM EDT
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $6.23M in the quarter ending March 31, 2026, a decrease of -96.07%. This brings the company's revenue in the last twelve months to $32.08M, down -83.20% year-over-year. In the year 2025, Stoke Therapeutics had annual revenue of $184.42M with 404.50% growth.
Revenue (ttm)
$32.08M
Revenue Growth
-83.20%
P/S Ratio
55.93
Revenue / Employee
$188,706
Employees
170
Market Cap
1.79B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184.42M | 147.87M | 404.50% |
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| Immunocore Holdings | 412.81M |
| AnaptysBio | 232.39M |
| Maravai LifeSciences Holdings | 204.73M |
| Zymeworks | 81.26M |
| Precigen | 31.60M |
| Generate Biomedicines | 30.30M |
| Zenas BioPharma | 10.00M |
STOK News
- 5 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 8 days ago - Stoke Therapeutics appoints McCauley as Chief Scientific Officer - TheFly
- 8 days ago - Stoke Therapeutics initiated with a Buy at Goldman Sachs - TheFly
- 21 days ago - Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR study - TheFly
- 21 days ago - Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - Business Wire
- 6 weeks ago - Stoke Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Stoke Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Stoke Therapeutics Transcript: AGM 2026 - Transcripts